Trials / Completed
CompletedNCT07146815
PolyCystic Ovary Syndrome as Suggested Risk Group for Non-Alcoholic Fatty Liver Disease
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 157 (actual)
- Sponsor
- Ziekenhuis Oost-Limburg · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
To study the prevalence, non-invasive diagnostics and evolution of non-alcoholic-fatty-liver-disease (NAFLD) in patients with polycystic ovary syndrome (PCOS)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | FibroScan | Performance of a FibroScan measurement to determine the prevalence of liver steatosis. |
| DIAGNOSTIC_TEST | MRI PDFF | Performance of an MRI-PDFF to determine amount of liver steatosis. |
Timeline
- Start date
- 2022-11-29
- Primary completion
- 2025-04-01
- Completion
- 2025-04-01
- First posted
- 2025-08-28
- Last updated
- 2025-08-28
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT07146815. Inclusion in this directory is not an endorsement.